{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:59:02Z","timestamp":1785131942806,"version":"3.55.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-026-03308-4","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T07:12:06Z","timestamp":1782717126000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Decoy oligonucleotide technology in cancer therapy: molecular mechanisms, challenges, and translational potential"],"prefix":"10.1007","volume":"43","author":[{"given":"Maryam","family":"Mahjoubin-Tehran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samaneh","family":"Rezaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0890-769X","authenticated-orcid":false,"given":"Prashant","family":"Kesharwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Sahebkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"issue":"11","key":"3308_CR1","doi-asserted-by":"publisher","first-page":"9663","DOI":"10.1007\/s11033-023-08809-3","volume":"50","author":"R Kaur","year":"2023","unstructured":"Kaur R, Bhardwaj A, Gupta S. Cancer treatment therapies: traditional to modern approaches to combat cancers. Mol Biol Rep. 2023;50(11):9663\u201376.","journal-title":"Mol Biol Rep"},{"key":"3308_CR2","doi-asserted-by":"publisher","first-page":"SII9","DOI":"10.1016\/S0140-6736(98)90327-0","volume":"351","author":"IF Tannock","year":"1998","unstructured":"Tannock IF. Conventional cancer therapy: promise broken or promise delayed? Lancet. 1998;351:SII9\u201316.","journal-title":"Lancet"},{"key":"3308_CR3","unstructured":"Nurgali K, Jagoe RT, Abalo R. Frontiers Media SA; 2018. p. 245."},{"key":"3308_CR4","doi-asserted-by":"publisher","first-page":"129742","DOI":"10.1016\/j.bmcl.2024.129742","volume":"104","author":"Q Dai","year":"2024","unstructured":"Dai Q, Yuan Z, Sun Q, Ao Z, He B, Jiang Y. Discovery of novel nucleoside derivatives as selective lysine acetyltransferase p300 inhibitors for cancer therapy. Bioorg Med Chem Lett. 2024;104:129742.","journal-title":"Bioorg Med Chem Lett"},{"issue":"11","key":"3308_CR5","doi-asserted-by":"publisher","first-page":"6001","DOI":"10.1016\/j.apsb.2025.08.003","volume":"15","author":"S Wang","year":"2025","unstructured":"Wang S, Ma D, Yang M, Zhang Y, Wang S, Zhou W. Arsenic trioxide-based nanoparticles for enhanced chemotherapy by activating pyroptosis. Acta Pharm Sinica B. 2025;15(11):6001\u201318.","journal-title":"Acta Pharm Sinica B"},{"issue":"12","key":"3308_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16121582","volume":"16","author":"C Feng","year":"1999","unstructured":"Feng C, Wang Y, Xu J, Zheng Y, Zhou W, Wang Y, et al. Precisely Tailoring Molecular Structure of Doxorubicin Prodrugs to Enable Stable Nanoassembly, Rapid Activation, and Potent Antitumor Effect. Pharmaceutics. 1999;1582. https:\/\/doi.org\/10.3390\/pharmaceutics16121582.","journal-title":"Pharmaceutics"},{"issue":"2","key":"3308_CR7","doi-asserted-by":"publisher","first-page":"108557","DOI":"10.1016\/j.cclet.2023.108557","volume":"35","author":"L Guo","year":"2024","unstructured":"Guo L, Ding J, Zhou W. Harnessing bacteria for tumor therapy: Current advances and challenges. Chin Chem Lett. 2024;35(2):108557.","journal-title":"Chin Chem Lett"},{"key":"3308_CR8","doi-asserted-by":"publisher","first-page":"119513","DOI":"10.1016\/j.ijpharm.2020.119513","volume":"585","author":"Y Nie","year":"2020","unstructured":"Nie Y, Li D, Peng Y, Wang S, Hu S, Liu M, et al. Metal organic framework coated MnO2 nanosheets delivering doxorubicin and self-activated DNAzyme for chemo-gene combinatorial treatment of cancer. Int J Pharm. 2020;585:119513.","journal-title":"Int J Pharm"},{"issue":"8","key":"3308_CR9","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1158\/2159-8290.CD-12-0191","volume":"2","author":"M Sen","year":"2012","unstructured":"Sen M, Thomas SM, Kim S, Yeh JI, Ferris RL, Johnson JT, et al. First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy. Cancer Discov. 2012;2(8):694\u2013705.","journal-title":"Cancer Discov"},{"key":"3308_CR10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.bcp.2017.06.122","volume":"144","author":"M Hecker","year":"2017","unstructured":"Hecker M, Wagner AH. Transcription factor decoy technology: A therapeutic update. Biochem Pharmacol. 2017;144:29\u201334.","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"3308_CR11","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/msb.2012.7","volume":"8","author":"TH Lee","year":"2012","unstructured":"Lee TH, Maheshri N. A regulatory role for repeated decoy transcription factor binding sites in target gene expression. Mol Syst Biol. 2012;8(1):576.","journal-title":"Mol Syst Biol"},{"issue":"25","key":"3308_CR12","doi-asserted-by":"publisher","first-page":"3954","DOI":"10.2174\/0929867330666230505154319","volume":"31","author":"S Rezaei","year":"2024","unstructured":"Rezaei S, Mahjoubin-Tehran M, Iratni R, Sahebkar A. Therapeutic Potential of Decoys for Prostate Cancers: A Review of Recent Updates. Curr Med Chem. 2024;31(25):3954\u201365.","journal-title":"Curr Med Chem"},{"issue":"3","key":"3308_CR13","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1007\/s13238-013-2084-3","volume":"4","author":"Y Fan","year":"2013","unstructured":"Fan Y, Mao R, Yang J. NF-\u03baB and STAT3 signaling pathways collaboratively link inflammation to cancer. Protein Cell. 2013;4(3):176\u201385.","journal-title":"Protein Cell"},{"key":"3308_CR14","doi-asserted-by":"publisher","unstructured":"Cheng Y, Wang L, Zhang S, et al. The investigation of Nf\u03bab inhibitors to block cell proliferation in OSCC cells lines. Curr Med Chem. 2025;32(33):7314\u201326. https:\/\/doi.org\/10.2174\/0109298673309489240816063313","DOI":"10.2174\/0109298673309489240816063313"},{"issue":"6","key":"3308_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2024.189207","volume":"1879","author":"D Shi","year":"2024","unstructured":"Shi D, Tao J, Man S, Zhang N, Ma L, Guo L, et al. Structure, function, signaling pathways and clinical therapeutics: The translational potential of STAT3 as a target for cancer therapy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2024;1879(6):189207.","journal-title":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"},{"key":"3308_CR16","doi-asserted-by":"publisher","first-page":"101042","DOI":"10.1016\/j.drup.2023.101042","volume":"73","author":"Y Li","year":"2024","unstructured":"Li Y, Zhao B, Peng J, Tang H, Wang S, Peng S, et al. Inhibition of NF-\u03baB signaling unveils novel strategies to overcome drug resistance in cancers. Drug Resist Updates. 2024;73:101042.","journal-title":"Drug Resist Updates"},{"issue":"1","key":"3308_CR17","first-page":"e28975","volume":"3","author":"MK Wendt","year":"2014","unstructured":"Wendt MK, Balanis N, Carlin CR, Schiemann WP. STAT3 and epithelial-mesenchymal transitions in carcinomas. Jakstat. 2014;3(1):e28975.","journal-title":"Jakstat"},{"issue":"1","key":"3308_CR18","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1186\/s12964-023-01207-z","volume":"21","author":"A Oh","year":"2023","unstructured":"Oh A, Pardo M, Rodriguez A, Yu C, Nguyen L, Liang O, et al. NF-\u03baB signaling in neoplastic transition from epithelial to mesenchymal phenotype. Cell Commun Signal. 2023;21(1):291.","journal-title":"Cell Commun Signal"},{"issue":"11","key":"3308_CR19","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1002\/ijc.29923","volume":"138","author":"K Banerjee","year":"2016","unstructured":"Banerjee K, Resat H. Constitutive activation of STAT3 in breast cancer cells: A review. Int J Cancer. 2016;138(11):2570\u20138.","journal-title":"Int J Cancer"},{"key":"3308_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15133338","author":"KT Chuang","year":"2023","unstructured":"Chuang KT, Chiou SS, Hsu SH. Recent Advances in Transcription Factors Biomarkers and Targeted Therapies Focusing on Epithelial-Mesenchymal Transition. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15133338.","journal-title":"Cancers (Basel)"},{"key":"3308_CR21","doi-asserted-by":"publisher","first-page":"1476030","DOI":"10.3389\/fimmu.2024.1476030","volume":"15","author":"Y Cao","year":"2024","unstructured":"Cao Y, Yi Y, Han C, Shi B. NF-\u03baB signaling pathway in tumor microenvironment. Front Immunol. 2024;15:1476030.","journal-title":"Front Immunol"},{"issue":"1","key":"3308_CR22","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12943-018-0928-4","volume":"18","author":"X Jiang","year":"2019","unstructured":"Jiang X, Wang J, Deng X, Xiong F, Ge J, Xiang B, et al. Role of the tumor microenvironment in PD-L1\/PD-1-mediated tumor immune escape. Mol Cancer. 2019;18(1):10.","journal-title":"Mol Cancer"},{"issue":"8","key":"3308_CR23","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/s41423-025-01310-w","volume":"22","author":"H Mao","year":"2025","unstructured":"Mao H, Zhao X, Sun SC. NF-\u03baB in inflammation and cancer. Cell Mol Immunol. 2025;22(8):811\u201339.","journal-title":"Cell Mol Immunol"},{"key":"3308_CR24","first-page":"2941","volume":"9","author":"XW Chen","year":"2015","unstructured":"Chen XW, Zhou SF. Inflammation, cytokines, the IL-17\/IL-6\/STAT3\/NF-\u03baB axis, and tumorigenesis. Drug Des Devel Ther. 2015;9:2941\u20136.","journal-title":"Drug Des Devel Ther"},{"key":"3308_CR25","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/msb.2011.56","volume":"7","author":"D Gaglio","year":"2011","unstructured":"Gaglio D, Metallo CM, Gameiro PA, Hiller K, Danna LS, Balestrieri C, et al. Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth. Mol Syst Biol. 2011;7:523.","journal-title":"Mol Syst Biol"},{"issue":"2","key":"3308_CR26","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/nrc.2017.118","volume":"18","author":"T Brabletz","year":"2018","unstructured":"Brabletz T, Kalluri R, Nieto MA, Weinberg RA. EMT in cancer. Nat Rev Cancer. 2018;18(2):128\u201334.","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"3308_CR27","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1111\/j.1349-7006.2004.tb03320.x","volume":"95","author":"T Oikawa","year":"2004","unstructured":"Oikawa T. ETS transcription factors: possible targets for cancer therapy. Cancer Sci. 2004;95(8):626\u201333.","journal-title":"Cancer Sci"},{"issue":"16","key":"3308_CR28","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1016\/j.ejca.2005.08.013","volume":"41","author":"A Seth","year":"2005","unstructured":"Seth A, Watson DK. ETS transcription factors and their emerging roles in human cancer. Eur J Cancer. 2005;41(16):2462\u201378.","journal-title":"Eur J Cancer"},{"key":"3308_CR29","doi-asserted-by":"publisher","first-page":"1526368","DOI":"10.3389\/fimmu.2025.1526368","volume":"16","author":"S Wang","year":"2025","unstructured":"Wang S, Wan L, Zhang X, Fang H, Zhang M, Li F, et al. ETS-1 in tumor immunology: implications for novel anti-cancer strategies. Front Immunol. 2025;16:1526368.","journal-title":"Front Immunol"},{"key":"3308_CR30","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1749-6632.2001.tb03934.x","volume":"947","author":"Y Sato","year":"2001","unstructured":"Sato Y, Teruyama K, Nakano T, Oda N, Abe M, Tanaka K, et al. Role of transcription factors in angiogenesis: Ets-1 promotes angiogenesis as well as endothelial apoptosis. Ann N Y Acad Sci. 2001;947:117\u201323.","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"3308_CR31","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S0304-3835(00)00559-0","volume":"160","author":"S Tsutsumi","year":"2000","unstructured":"Tsutsumi S, Kuwano H, Asao T, Nagashima K, Shimura T, Mochiki E. Expression of Ets-1 angiogenesis-related protein in gastric cancer. Cancer Lett. 2000;160(1):45\u201350.","journal-title":"Cancer Lett"},{"issue":"1","key":"3308_CR32","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nrd2781","volume":"8","author":"V Baud","year":"2009","unstructured":"Baud V, Karin M. Is NF-\u03baB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov. 2009;8(1):33\u201340.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"3308_CR33","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/j.ymthe.2020.11.026","volume":"29","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Zhao X, Wang D, Moreira D, Su YL, Alcantara M, et al. Targeted In Vivo Delivery of NF-\u03baB Decoy Inhibitor Augments Sensitivity of B Cell Lymphoma to Therapy. Mol Ther. 2021;29(3):1214\u201325.","journal-title":"Mol Ther"},{"key":"3308_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24087493","author":"Q Zhang","year":"2023","unstructured":"Zhang Q, Sioud M. Tumor-Associated Macrophage Subsets: Shaping Polarization and Targeting. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24087493.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"3308_CR35","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3109\/1061186X.2014.880443","volume":"22","author":"Y Kono","year":"2014","unstructured":"Kono Y, Kawakami S, Higuchi Y, Maruyama K, Yamashita F, Hashida M. Tumour-associated macrophages targeted transfection with NF-\u03baB decoy\/mannose-modified bubble lipoplexes inhibits tumour growth in tumour-bearing mice. J Drug Target. 2014;22(5):439\u201349.","journal-title":"J Drug Target"},{"issue":"2","key":"3308_CR36","doi-asserted-by":"publisher","first-page":"708","DOI":"10.3390\/cancers6020708","volume":"6","author":"D Harada","year":"2014","unstructured":"Harada D, Takigawa N, Kiura K. The Role of STAT3 in Non-Small Cell Lung Cancer. Cancers (Basel). 2014;6(2):708\u201322.","journal-title":"Cancers (Basel)"},{"issue":"9","key":"3308_CR37","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1158\/1940-6207.CAPR-20-0033","volume":"13","author":"C Njatcha","year":"2020","unstructured":"Njatcha C, Farooqui M, Almotlak AA, Siegfried JM. Prevention of Tobacco Carcinogen-Induced Lung Tumor Development by a Novel STAT3 Decoy Inhibitor. Cancer Prev Res (Phila). 2020;13(9):735\u201346.","journal-title":"Cancer Prev Res (Phila)"},{"issue":"1","key":"3308_CR38","doi-asserted-by":"publisher","first-page":"46","DOI":"10.2119\/molmed.2013.00104","volume":"20","author":"M Sen","year":"2014","unstructured":"Sen M, Paul K, Freilino ML, Li H, Li C, Johnson DE, et al. Systemic administration of a cyclic signal transducer and activator of transcription 3 (STAT3) decoy oligonucleotide inhibits tumor growth without inducing toxicological effects. Mol Med. 2014;20(1):46\u201356.","journal-title":"Mol Med"},{"issue":"3","key":"3308_CR39","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/1759-7714.14268","volume":"13","author":"X Huang","year":"2022","unstructured":"Huang X, Cao J, Zu X. Tumor-associated macrophages: An important player in breast cancer progression. Thorac Cancer. 2022;13(3):269\u201376.","journal-title":"Thorac Cancer"},{"issue":"3","key":"3308_CR40","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.imbio.2005.11.004","volume":"211","author":"Z Sun","year":"2006","unstructured":"Sun Z, Yao Z, Liu S, Tang H, Yan X. An oligonucleotide decoy for Stat3 activates the immune response of macrophages to breast cancer. Immunobiology. 2006;211(3):199\u2013209.","journal-title":"Immunobiology"},{"issue":"6","key":"3308_CR41","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s00280-008-0823-6","volume":"63","author":"M Sen","year":"2009","unstructured":"Sen M, Tosca PJ, Zwayer C, Ryan MJ, Johnson JD, Knostman KA, et al. Lack of toxicity of a STAT3 decoy oligonucleotide. Cancer Chemother Pharmacol. 2009;63(6):983\u201395.","journal-title":"Cancer Chemother Pharmacol"},{"key":"3308_CR42","volume-title":"Seminars in oncology","author":"J Luo","year":"2021","unstructured":"Luo J. KRAS mutation in pancreatic cancer. In: Seminars in oncology. Elsevier; 2021."},{"key":"3308_CR43","doi-asserted-by":"crossref","unstructured":"Xodo LE. Quadruplex nucleic acids in KRAS targeted-cancer therapy. Annual Reports in Medicinal Chemistry. 54: Elsevier; 2020. pp. 325\u2009\u2013\u200959.","DOI":"10.1016\/bs.armc.2020.04.004"},{"issue":"6","key":"3308_CR44","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1111\/ajco.13748","volume":"18","author":"C Zheng","year":"2022","unstructured":"Zheng C, Wu H, Jin S, Li D, Tan S, Zhu X. Roles of Myc-associated zinc finger protein in malignant tumors. Asia\u2010Pacific J Clin Oncol. 2022;18(6):506\u201314.","journal-title":"Asia\u2010Pacific J Clin Oncol"},{"issue":"7","key":"3308_CR45","doi-asserted-by":"publisher","first-page":"4049","DOI":"10.1093\/nar\/gkt127","volume":"41","author":"S Cogoi","year":"2013","unstructured":"Cogoi S, Zorzet S, Rapozzi V, G\u00e9ci I, Pedersen EB, Xodo LE. MAZ-binding G4-decoy with locked nucleic acid and twisted intercalating nucleic acid modifications suppresses KRAS in pancreatic cancer cells and delays tumor growth in mice. Nucleic Acids Res. 2013;41(7):4049\u201364.","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"3308_CR46","doi-asserted-by":"publisher","first-page":"188872","DOI":"10.1016\/j.bbcan.2023.188872","volume":"1878","author":"Y Wang","year":"2023","unstructured":"Wang Y, Huang Z, Sun M, Huang W, Xia L. ETS transcription factors: multifaceted players from cancer progression to Tumor immunity. Biochim et Biophys Acta (BBA)-Reviews Cancer. 2023;1878(3):188872.","journal-title":"Biochim et Biophys Acta (BBA)-Reviews Cancer"},{"issue":"7","key":"3308_CR47","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1002\/ijc.22870","volume":"121","author":"H Taniguchi","year":"2007","unstructured":"Taniguchi H, Fujiwara Y, Doki Y, Sugita Y, Sohma I, Miyata H, et al. Gene therapy using ets-1 transcription factor decoy for peritoneal dissemination of gastric cancer. Int J Cancer. 2007;121(7):1609\u201317.","journal-title":"Int J Cancer"},{"issue":"4","key":"3308_CR48","doi-asserted-by":"publisher","first-page":"103529","DOI":"10.1016\/j.jpet.2025.103529","volume":"392","author":"J Hong","year":"2025","unstructured":"Hong J, Wu Y, Li M, Man KF, Song D, Koh SB. cAMP response element-binding protein: A credible cancer drug target. J Pharmacol Exp Ther. 2025;392(4):103529.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"3308_CR49","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1074\/jbc.274.3.1573","volume":"274","author":"YG Park","year":"1999","unstructured":"Park YG, Nesterova M, Agrawal S, Cho-Chung YS. Dual blockade of cyclic AMP response element-(CRE) and AP-1-directed transcription by CRE-transcription factor decoy oligonucleotide: gene-specific inhibition of tumor growth. J Biol Chem. 1999;274(3):1573\u201380.","journal-title":"J Biol Chem"},{"key":"3308_CR50","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","volume":"87","author":"RS Geary","year":"2015","unstructured":"Geary RS, Norris D, Yu R, Bennett CF. Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv Drug Deliv Rev. 2015;87:46\u201351.","journal-title":"Adv Drug Deliv Rev"},{"key":"3308_CR51","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1146\/annurev-pharmtox-010818-021050","volume":"59","author":"CIE Smith","year":"2019","unstructured":"Smith CIE, Zain R. Therapeutic Oligonucleotides: State of the Art. Annu Rev Pharmacol Toxicol. 2019;59:605\u201330.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"3308_CR52","doi-asserted-by":"publisher","unstructured":"Katari O, Kumar K, Bhamble S, Jain S. Gemini surfactants as next-generation drug carriers in cancer management. Expert Opin Drug Deliv. 2024;21(7):1029\u201351. https:\/\/doi.org\/10.1080\/17425247.2024.2384037","DOI":"10.1080\/17425247.2024.2384037"},{"key":"3308_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2023.123276","author":"MS Khan","year":"2023","unstructured":"Khan MS, Gowda BHJ, Nasir N, Wahab S, Pichika MR, Sahebkar A, et al. Advancements in dextran-based nanocarriers for treatment and imaging of breast cancer. International Journal of Pharmaceutics. 2023. https:\/\/doi.org\/10.1016\/j.ijpharm.2023.123276.","journal-title":"International Journal of Pharmaceutics"},{"key":"3308_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2023.104562","author":"M Sanati","year":"2023","unstructured":"Sanati M, Afshari AR, Aminyavari S, Kesharwani P, Jamialahmadi T, Sahebkar A. RGD-engineered nanoparticles as an innovative drug delivery system in cancer therapy. Journal of Drug Delivery Science and Technology. 2023. https:\/\/doi.org\/10.1016\/j.jddst.2023.104562.","journal-title":"Journal of Drug Delivery Science and Technology"},{"key":"3308_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpolymj.2021.110683","author":"V Singh","year":"2021","unstructured":"Singh V, Sahebkar A, Kesharwani P. Poly (propylene imine) dendrimer as an emerging polymeric nanocarrier for anticancer drug and gene delivery. European Polymer Journal. 2021. https:\/\/doi.org\/10.1016\/j.eurpolymj.2021.110683.","journal-title":"European Polymer Journal"},{"key":"3308_CR56","doi-asserted-by":"publisher","first-page":"100023","DOI":"10.1016\/j.medidd.2020.100023","volume":"6","author":"S Zhou","year":"2020","unstructured":"Zhou S, Chen W, Cole J, Zhu G. Delivery of nucleic acid therapeutics for cancer immunotherapy. Med Drug Discovery. 2020;6:100023.","journal-title":"Med Drug Discovery"},{"issue":"1","key":"3308_CR57","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ejpb.2008.03.012","volume":"70","author":"G De Rosa","year":"2008","unstructured":"De Rosa G, De Stefano D, Laguardia V, Arpicco S, Simeon V, Carnuccio R, et al. Novel cationic liposome formulation for the delivery of an oligonucleotide decoy to NF-kappaB into activated macrophages. Eur J Pharm Biopharm. 2008;70(1):7\u201318.","journal-title":"Eur J Pharm Biopharm"},{"issue":"9","key":"3308_CR58","doi-asserted-by":"publisher","first-page":"e71178","DOI":"10.1111\/jcmm.71178","volume":"30","author":"M Mahjoubin-Tehran","year":"2026","unstructured":"Mahjoubin-Tehran M, Rezaei S, Sukhorukov VN, Jalili A, Kesharwani P, Sahebkar A. AP-1-Targeting Decoy Oligonucleotides: Mechanisms and Therapeutic Potential as Modulators of Inflammatory Pathways. J Cell Mol Med. 2026;30(9):e71178.","journal-title":"J Cell Mol Med"},{"issue":"8","key":"3308_CR59","doi-asserted-by":"publisher","first-page":"745","DOI":"10.2174\/1389450043345083","volume":"5","author":"R Crinelli","year":"2004","unstructured":"Crinelli R, Bianchi M, Gentilini L, Palma L, Magnani M. Locked nucleic acids (LNA): versatile tools for designing oligonucleotide decoys with high stability and affinity. Curr Drug Targets. 2004;5(8):745\u201352.","journal-title":"Curr Drug Targets"},{"key":"3308_CR60","doi-asserted-by":"publisher","first-page":"115710","DOI":"10.1016\/j.expneurol.2026.115710","volume":"401","author":"M Mahjoubin-Tehran","year":"2026","unstructured":"Mahjoubin-Tehran M, Rezaei S, Almahmeed W, Aromolaran AS, Kesharwani P, Sahebkar A. Decoy oligodeoxynucleotides and peptides as a promising approach for managing myocardial infarction and stroke. Exp Neurol. 2026;401:115710.","journal-title":"Exp Neurol"},{"issue":"8","key":"3308_CR61","doi-asserted-by":"publisher","first-page":"619","DOI":"10.2174\/1389450033490821","volume":"4","author":"IK Lee","year":"2003","unstructured":"Lee IK, Ahn JD, Kim HS, Park JY, Lee KU. Advantages of the circular dumbbell decoy in gene therapy and studies of gene regulation. Curr Drug Targets. 2003;4(8):619\u201323.","journal-title":"Curr Drug Targets"},{"issue":"2","key":"3308_CR62","first-page":"107","volume":"5","author":"N Tomita","year":"2003","unstructured":"Tomita N, Tomita T, Yuyama K, Tougan T, Tajima T, Ogihara T, et al. Development of novel decoy oligonucleotides: advantages of circular dumb-bell decoy. Curr Opin Mol Ther. 2003;5(2):107\u201312.","journal-title":"Curr Opin Mol Ther"},{"issue":"1","key":"3308_CR63","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.drudis.2019.10.008","volume":"25","author":"M Mahjoubin-Tehran","year":"2020","unstructured":"Mahjoubin-Tehran M, Rezaei S, Jalili A, Aghaee-Bakhtiari SH, Sahebkar A. Decoy oligodeoxynucleotide technology: an emerging paradigm for breast cancer treatment. Drug Discov Today. 2020;25(1):195\u2013200.","journal-title":"Drug Discov Today"},{"issue":"3","key":"3308_CR64","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.drudis.2020.01.010","volume":"25","author":"M Mahjoubin-Tehran","year":"2020","unstructured":"Mahjoubin-Tehran M, Rezaei S, Jalili A, Aghaee-Bakhtiari SH, Orafai HM, Jamialahmadi T, et al. Peptide decoys: A new technology offering therapeutic opportunities for breast cancer. Drug Discovery Today. 2020;25(3):593\u20138.","journal-title":"Drug Discovery Today"},{"issue":"5","key":"3308_CR65","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.drudis.2019.04.007","volume":"24","author":"F Vahdat Lasemi","year":"2019","unstructured":"Vahdat Lasemi F, Mahjoubin Tehran M, Aghaee-Bakhtiari SH, Jalili A, Jaafari MR, Sahebkar A. Harnessing nucleic acid-based therapeutics for atherosclerotic cardiovascular disease: state of the art. Drug Discovery Today. 2019;24(5):1116\u201331.","journal-title":"Drug Discovery Today"},{"issue":"6","key":"3308_CR66","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1007\/s11095-009-9855-9","volume":"26","author":"W Jiskoot","year":"2009","unstructured":"Jiskoot W, van Schie RM, Carstens MG, Schellekens H. Immunological risk of injectable drug delivery systems. Pharm Res. 2009;26(6):1303\u201314.","journal-title":"Pharm Res"},{"issue":"11","key":"3308_CR67","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.2174\/1389203720666190830162149","volume":"20","author":"K Feh\u00e9r","year":"2019","unstructured":"Feh\u00e9r K. Single Stranded DNA Immune Modulators with Unmethylated CpG Motifs: Structure and Molecular Recognition by Toll-Like Receptor 9. Curr Protein Pept Sci. 2019;20(11):1060\u20138.","journal-title":"Curr Protein Pept Sci"},{"issue":"8","key":"3308_CR68","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1080\/14737140.2021.1915136","volume":"21","author":"Y Jin","year":"2021","unstructured":"Jin Y, Zhuang Y, Dong X, Liu M. Development of CpG oligodeoxynucleotide TLR9 agonists in anti-cancer therapy. Expert Rev Anticancer Ther. 2021;21(8):841\u201351.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"3308_CR69","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1177\/0192623314551840","volume":"43","author":"KS Frazier","year":"2015","unstructured":"Frazier KS. Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist\u2019s perspective. Toxicol Pathol. 2015;43(1):78\u201389.","journal-title":"Toxicol Pathol"},{"issue":"4","key":"3308_CR70","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1021\/mp800049w","volume":"5","author":"S-D Li","year":"2008","unstructured":"Li S-D, Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm. 2008;5(4):496\u2013504.","journal-title":"Mol Pharm"},{"issue":"1","key":"3308_CR71","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s11095-022-03433-5","volume":"40","author":"A D\u2019Souza","year":"2023","unstructured":"D\u2019Souza A, Nozohouri S, Bleier BS, Amiji MM. CNS delivery of nucleic acid therapeutics: beyond the blood\u2013brain barrier and towards specific cellular targeting. Pharm Res. 2023;40(1):77\u2013105.","journal-title":"Pharm Res"},{"issue":"3","key":"3308_CR72","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1021\/acs.accounts.2c00464","volume":"56","author":"M Lu","year":"2023","unstructured":"Lu M, Xing H, Zheng A, Huang Y, Liang X-J. Overcoming pharmaceutical bottlenecks for nucleic acid drug development. Acc Chem Res. 2023;56(3):224\u201336.","journal-title":"Acc Chem Res"},{"issue":"1","key":"3308_CR73","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00011-025-02021-8","volume":"74","author":"M Mahjoubin-Tehran","year":"2025","unstructured":"Mahjoubin-Tehran M, Rezaei S, Butler AE, Sahebkar A. Decoy oligonucleotides targeting NF-\u03baB: a promising therapeutic approach for inflammatory diseases. Inflamm Res. 2025;74(1):47.","journal-title":"Inflamm Res"},{"issue":"9","key":"3308_CR74","doi-asserted-by":"publisher","first-page":"4420","DOI":"10.3390\/ijms22094420","volume":"22","author":"M Mahjoubin-Tehran","year":"2021","unstructured":"Mahjoubin-Tehran M, Teng Y, Jalili A, Aghaee-Bakhtiari SH, Markin AM, Sahebkar A. Decoy technology as a promising therapeutic tool for atherosclerosis. Int J Mol Sci. 2021;22(9):4420.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"3308_CR75","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/bcp.12987","volume":"82","author":"K Sridharan","year":"2016","unstructured":"Sridharan K, Gogtay NJ. Therapeutic nucleic acids: current clinical status. Br J Clin Pharmacol. 2016;82(3):659\u201372.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"3308_CR76","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/jps.22243","volume":"100","author":"L Xu","year":"2011","unstructured":"Xu L, Anchordoquy T. Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics. J Pharm Sci. 2011;100(1):38\u201352.","journal-title":"J Pharm Sci"},{"key":"3308_CR77","doi-asserted-by":"publisher","DOI":"10.2147\/ijn.s466042","author":"Y Wang","year":"2013","unstructured":"Wang Y, Xu Y, Song J, Liu X, Liu S, Yang N, Wang L, Liu Y, Zhao Y, Zhou W, Zhang Y. Tumor cell-targeting and tumor microenvironment-responsive nanoplatforms for the multimodal imaging-guided photodynamic\/photothermal\/chemodynamic treatment of cervical cancer. Int J Nanomed. 2024;19:5837\u201358. https:\/\/doi.org\/10.2147\/ijn.s466042","journal-title":"Int J Nanomed"},{"key":"3308_CR78","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.jconrel.2024.07.067","volume":"373","author":"X Hao","year":"2024","unstructured":"Hao X, Jiang B, Wu J, Xiang D, Xiong Z, Li C, et al. Nanomaterials for bone metastasis. J Controlled Release. 2024;373:640\u201351.","journal-title":"J Controlled Release"},{"key":"3308_CR79","doi-asserted-by":"publisher","unstructured":"Qin J, Jiang Z. Ultrasound-responsive calcium copper phosphate nanomaterials induce tumor cell death via the synergistic release of copper and calcium. Int J Mol Sci. 2026;27(4):2016. https:\/\/doi.org\/10.3390\/ijms27042016.","DOI":"10.3390\/ijms27042016"},{"issue":"5","key":"3308_CR80","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1124\/mol.106.024273","volume":"70","author":"H Gao","year":"2006","unstructured":"Gao H, Xiao J, Sun Q, Lin H, Bai Y, Yang L, et al. A single decoy oligodeoxynucleotides targeting multiple oncoproteins produces strong anticancer effects. Mol Pharmacol. 2006;70(5):1621\u20139.","journal-title":"Mol Pharmacol"},{"key":"3308_CR81","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1146\/annurev-biochem-060815-014607","volume":"85","author":"H Wang","year":"2016","unstructured":"Wang H, La Russa M, Qi LS. CRISPR\/Cas9 in Genome Editing and Beyond. Annu Rev Biochem. 2016;85:227\u201364.","journal-title":"Annu Rev Biochem"},{"issue":"1","key":"3308_CR82","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1021\/acs.joc.0c02291","volume":"86","author":"BI Andrews","year":"2021","unstructured":"Andrews BI, Antia FD, Brueggemeier SB, Diorazio LJ, Koenig SG, Kopach ME, et al. Sustainability Challenges and Opportunities in Oligonucleotide Manufacturing. J Org Chem. 2021;86(1):49\u201361.","journal-title":"J Org Chem"},{"issue":"6692","key":"3308_CR83","doi-asserted-by":"publisher","first-page":"eadl4015","DOI":"10.1126\/science.adl4015","volume":"384","author":"R Obexer","year":"2024","unstructured":"Obexer R, Nassir M, Moody ER, Baran PS, Lovelock SL. Modern approaches to therapeutic oligonucleotide manufacturing. Science. 2024;384(6692):eadl4015.","journal-title":"Science"},{"issue":"9","key":"3308_CR84","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.3390\/ijms21093233","volume":"21","author":"K Bukowski","year":"2020","unstructured":"Bukowski K, Kciuk M, Kontek R. Mechanisms of multidrug resistance in cancer chemotherapy. Int J Mol Sci. 2020;21(9):3233.","journal-title":"Int J Mol Sci"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03308-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-026-03308-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03308-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:01:53Z","timestamp":1785128513000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-026-03308-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":84,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["3308"],"URL":"https:\/\/doi.org\/10.1007\/s12032-026-03308-4","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"assertion":[{"value":"5 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"To revise the manuscript, we used Google NotebookLM to assist with in-depth literature exploration and article organization, and QuillBot to improve language clarity and writing quality. All scientific content, interpretations, conclusions, and final revisions were critically reviewed by the authors, who take full responsibility for the accuracy of the manuscript.","order":2,"name":"Ethics","label":"<b>Declaration of Generative AI and AI-Assisted Technologies<\/b>","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"205"}}